Matches in SemOpenAlex for { <https://semopenalex.org/work/W2232060480> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2232060480 endingPage "4123" @default.
- W2232060480 startingPage "4123" @default.
- W2232060480 abstract "4123 Background: Malignancies of the gallbladder and biliary tract are uncommon in the United States, but are common in certain Japanese, Chilean, and Native American populations. Most patients present with advanced disease and are not candidates for potentially curative resection. Response rates range from 10–20% for patients receiving palliative chemotherapy, indicating the need for new therapeutic regimens. Patients and Methods: We prospectively studied capecitabine (Xeloda) 750mg/m2 twice daily on days 1–14 in combination with oxaliplatin 130mg/m2 on day 1 every 21 days in patients (pts) with unresectable or recurrent cholangiocarcinoma, to determine the response rate (RR), safety, and survival of pts treated with XELOX. Twenty-six pts were enrolled; 8 men and 18 women with a median age of 63(range 46–77). Pathologically 96% were adenocarcinoma and 4% were squamous carcinoma. Pts were stratified into 2 arms according to prior chemotherapy (8 pts) versus no prior chemotherapy (18 pts). Results: Twenty-one pts were evaluable for response and 26 pts were evaluable for toxicity. The overall RR was 19% (4/21). RR with and without prior therapy were 0%(0/6) and 26.6%(4/15), respectively. Following 3 courses of therapy 38% had stable disease and 43% had disease progression. Grade 1 neurotoxicity, diarrhea, anorexia, and nausea, were common. Grade 3 fatigue and diarrhea occurred in 23% and 8% of the pts respectively. Following treatment of 12 pts the starting dose of oxaliplatin was reduced to 100mg/m2 after prolonged myelosuppression, fatigue, and decreased PS were observed at the 130mg/m2 dose. Conclusions: With careful attention to dose XELOX is well tolerated. A RR of 26.6% in previously untreated pts is encouraging. XELOX should be considered an active regimen in the treatment of unresectable gallbladder cancer and cholangiocarcinoma. Accrual will continue to 50 pts and survival data analyzed. The toxicity profile is similar to that seen in other malignancies. No significant financial relationships to disclose." @default.
- W2232060480 created "2016-06-24" @default.
- W2232060480 creator A5039226600 @default.
- W2232060480 creator A5055379352 @default.
- W2232060480 creator A5072207853 @default.
- W2232060480 creator A5074174096 @default.
- W2232060480 creator A5084427458 @default.
- W2232060480 creator A5087376683 @default.
- W2232060480 date "2005-06-01" @default.
- W2232060480 modified "2023-09-26" @default.
- W2232060480 title "A phase II study of oxaliplatin and capecitabine (XELOX) in patients with unresectable cholangiocarcinoma, including carcinoma of the gallbladder and biliary tract" @default.
- W2232060480 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.4123" @default.
- W2232060480 hasPublicationYear "2005" @default.
- W2232060480 type Work @default.
- W2232060480 sameAs 2232060480 @default.
- W2232060480 citedByCount "4" @default.
- W2232060480 countsByYear W22320604802012 @default.
- W2232060480 crossrefType "journal-article" @default.
- W2232060480 hasAuthorship W2232060480A5039226600 @default.
- W2232060480 hasAuthorship W2232060480A5055379352 @default.
- W2232060480 hasAuthorship W2232060480A5072207853 @default.
- W2232060480 hasAuthorship W2232060480A5074174096 @default.
- W2232060480 hasAuthorship W2232060480A5084427458 @default.
- W2232060480 hasAuthorship W2232060480A5087376683 @default.
- W2232060480 hasConcept C121608353 @default.
- W2232060480 hasConcept C126322002 @default.
- W2232060480 hasConcept C141071460 @default.
- W2232060480 hasConcept C143998085 @default.
- W2232060480 hasConcept C2776534502 @default.
- W2232060480 hasConcept C2776694085 @default.
- W2232060480 hasConcept C2777148285 @default.
- W2232060480 hasConcept C2777909004 @default.
- W2232060480 hasConcept C2778654693 @default.
- W2232060480 hasConcept C2779802037 @default.
- W2232060480 hasConcept C2780580376 @default.
- W2232060480 hasConcept C2780962732 @default.
- W2232060480 hasConcept C31760486 @default.
- W2232060480 hasConcept C526805850 @default.
- W2232060480 hasConcept C71924100 @default.
- W2232060480 hasConcept C90924648 @default.
- W2232060480 hasConceptScore W2232060480C121608353 @default.
- W2232060480 hasConceptScore W2232060480C126322002 @default.
- W2232060480 hasConceptScore W2232060480C141071460 @default.
- W2232060480 hasConceptScore W2232060480C143998085 @default.
- W2232060480 hasConceptScore W2232060480C2776534502 @default.
- W2232060480 hasConceptScore W2232060480C2776694085 @default.
- W2232060480 hasConceptScore W2232060480C2777148285 @default.
- W2232060480 hasConceptScore W2232060480C2777909004 @default.
- W2232060480 hasConceptScore W2232060480C2778654693 @default.
- W2232060480 hasConceptScore W2232060480C2779802037 @default.
- W2232060480 hasConceptScore W2232060480C2780580376 @default.
- W2232060480 hasConceptScore W2232060480C2780962732 @default.
- W2232060480 hasConceptScore W2232060480C31760486 @default.
- W2232060480 hasConceptScore W2232060480C526805850 @default.
- W2232060480 hasConceptScore W2232060480C71924100 @default.
- W2232060480 hasConceptScore W2232060480C90924648 @default.
- W2232060480 hasIssue "16_suppl" @default.
- W2232060480 hasLocation W22320604801 @default.
- W2232060480 hasOpenAccess W2232060480 @default.
- W2232060480 hasPrimaryLocation W22320604801 @default.
- W2232060480 hasRelatedWork W2007304396 @default.
- W2232060480 hasRelatedWork W2061416514 @default.
- W2232060480 hasRelatedWork W2063254551 @default.
- W2232060480 hasRelatedWork W2160763249 @default.
- W2232060480 hasRelatedWork W2232060480 @default.
- W2232060480 hasRelatedWork W2309328686 @default.
- W2232060480 hasRelatedWork W2320562621 @default.
- W2232060480 hasRelatedWork W2417717847 @default.
- W2232060480 hasRelatedWork W2582045368 @default.
- W2232060480 hasRelatedWork W2999149094 @default.
- W2232060480 hasVolume "23" @default.
- W2232060480 isParatext "false" @default.
- W2232060480 isRetracted "false" @default.
- W2232060480 magId "2232060480" @default.
- W2232060480 workType "article" @default.